258.35
price down icon6.58%   -18.20
after-market Dopo l'orario di chiusura: 258.35
loading

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

pulisher
May 08, 2025

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga

May 08, 2025
pulisher
May 08, 2025

LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - ADVFN

May 08, 2025
pulisher
May 08, 2025

Dysautonomia Market Forecasted to Surge in Coming Years, - openPR.com

May 08, 2025
pulisher
May 08, 2025

Porphyria Treatment Market Grows with Targeted Rare Disease - openPR.com

May 08, 2025
pulisher
May 08, 2025

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications - Pharma Voice

May 08, 2025
pulisher
May 08, 2025

Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

U.S. Transthyretin Amyloidosis Treatment Market Set to Witness - openPR.com

May 07, 2025
pulisher
May 07, 2025

Coagulation factor deficiency Market: Epidemiology, - openPR.com

May 07, 2025
pulisher
May 06, 2025

Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - simplywall.st

May 06, 2025
pulisher
May 06, 2025

H.C. Wainwright maintains Alnylam stock Buy rating, $500 target By Investing.com - Investing.com UK

May 06, 2025
pulisher
May 06, 2025

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN

May 06, 2025
pulisher
May 05, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health C - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference - BioSpace

May 05, 2025
pulisher
May 05, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference | ALNY Stock News - GuruFocus

May 05, 2025
pulisher
May 04, 2025

Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report - Yahoo Finance

May 04, 2025
pulisher
May 03, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised by UBS | ALNY Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga

May 02, 2025
pulisher
May 02, 2025

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

UBS Boosts Alnylam (ALNY) Price Target Amid Promising Early Launch Trends | ALNY Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised to $325 by Ch - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised to $325 by Chardan Capital | ALNY Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga

May 02, 2025
pulisher
May 02, 2025

UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlig - GuruFocus

May 02, 2025
pulisher
May 01, 2025

Alnylam: Q1 Earnings Snapshot - MySA

May 01, 2025
pulisher
May 01, 2025

Alnylam Earnings: Launch of Amvuttra for ATTR-CM Underway; Fair Value Up to $245 From $223 - Morningstar

May 01, 2025
pulisher
May 01, 2025

Narrow-Moat Alnylam's Strong Patient Uptake Drives Growth; Diverse Pipeline Makes Progress - Morningstar

May 01, 2025
pulisher
May 01, 2025

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals Reports Strong Start to 2025 - TipRanks

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025
pulisher
May 01, 2025

Alnylam (ALNY): Price Target Raised Amid Promising Amvuttra Laun - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals (ALNY) Reports Strong Q1 2025 Growth - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALNY) - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga

May 01, 2025
pulisher
May 01, 2025

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Alnylam Q1 2025 beats EPS forecast, stock drops - Investing.com

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Alnylam Q1 2025 slides: 28% revenue growth as AMVUTTRA drives TTR franchise expansion - Investing.com

May 01, 2025
pulisher
May 01, 2025

Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

ALNYLAM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
May 01, 2025

We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet - simplywall.st

May 01, 2025
pulisher
Apr 30, 2025

Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive

Apr 30, 2025
pulisher
Apr 30, 2025

Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News

Apr 30, 2025
pulisher
Apr 29, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN

Apr 29, 2025
pulisher
Apr 29, 2025

Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

Alnylam (ALNY) and Halozyme (HALO) Secure EMA Panel Endorsements - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com

Apr 29, 2025
pulisher
Apr 28, 2025

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe - simplywall.st

Apr 28, 2025
biotechnology ONC
$235.94
price up icon 1.59%
$569.12
price down icon 8.64%
$94.78
price up icon 2.13%
$24.65
price up icon 1.48%
$33.10
price up icon 1.07%
Capitalizzazione:     |  Volume (24 ore):